Increased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: A nationwide population-based cohort study

Journal of the American Academy of Dermatology

Volumn 70, Issue 4, 2014, Pages 691-698

  Lee, Meng Sui ^a,b   Lin, Ruey Yi ^a   Lai, Mei Shu ^c  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

diabetes mellitus; methotrexate; National Health Insurance Research Database; psoriasis; severity; thiazide

Indexed keywords

AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOSPORIN; HYDROXYUREA; METHOTREXATE; MYCOPHENOLIC ACID; PSORALEN; RETINOID; THIAZIDE DIURETIC AGENT;

ADULT; AGE; ARTICLE; CHRONIC PANCREATITIS; COMORBIDITY; CUSHING DISEASE; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PSORIASIS; PUVA; RISK FACTOR; ULTRAVIOLET A RADIATION;

DIABETES MELLITUS; METHOTREXATE; NATIONAL HEALTH INSURANCE RESEARCH DATABASE; PSORIASIS; SEVERITY; THIAZIDE;

ADULT; AGE DISTRIBUTION; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; COMORBIDITY; CONFIDENCE INTERVALS; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METHOTREXATE; MIDDLE AGED; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PSORIASIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; STATISTICS, NONPARAMETRIC; TAIWAN; THIAZIDES;

EID: 84896079118     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2013.11.023     Document Type: Article

References (40)

1. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001;15:16-7. (Pubitemid 32842766)
2. Chang YT, Chen TJ, Liu PC, Chen YC, Chen YJ, Huang YL, et al. Epidemiological study of psoriasis in the national health insurance database in Taiwan. Acta Derm Venereol 2009;89:262-6.
3. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006;126:2194-201. (Pubitemid 44413165)
4. Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Arch Dermatol 2001;137:778-83. (Pubitemid 32577862)
5. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens 2013;31:433-42.
6. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41. (Pubitemid 44547793)
7. Gelfand JM, Dommasch ED, Shin DB, Azfar RS, Kurd SK, Wang X, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009;129:2411-8.
8. Alsufyani MA, Golant AK, Lebwohl M. Psoriasis and the metabolic syndrome. Dermatol Ther 2010;23:137-43.
9. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome: a cross-sectional study. Dermatology 2008;216:152-5. (Pubitemid 351158580)
10. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis: results from the national health and nutrition examination survey, 2003-2006. Arch Dermatol 2011;147:419-24.
11. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298:321-8.
12. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007;143:1493-9. (Pubitemid 350277763)
13. Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009;145:700-3.
14. Boehncke S, Thaci D, Beschmann H, Ludwig RJ, Ackermann H, Badenhoop K, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007;157:1249-51. (Pubitemid 350115673)
15. Karadag AS, Yavuz B, Ertugrul DT, Akin KO, Yalcin AA, Deveci OS, et al. Is psoriasis a pre-atherosclerotic disease? Increased insulin resistance and impaired endothelial function in patients with psoriasis. Int J Dermatol 2010;49:642-6.
16. Ucak S, Ekmekci TR, Basat O, Koslu A, Altuntas Y. Comparison of various insulin sensitivity indices in psoriatic patients and their relationship with type of psoriasis. J Eur Acad Dermatol Venereol 2006;20:517-22.
17. Buckingham BA, Sandborg CI. A randomized trial of methotrexate in newly diagnosed patients with type 1 diabetes mellitus. Clin Immunol 2000;96:86-90. (Pubitemid 30612775)
18. Dufer M, Krippeit-Drews P, Lembert N, Idahl LA, Drews G. Diabetogenic effect of cyclosporin A is mediated by interference with mitochondrial function of pancreatic B-cells. Mol Pharmacol 2001;60:873-9. (Pubitemid 32903977)
19. Burke TA, Sturkenboom MC, Ohman-Strickland PA, Wentworth CE, Rhoads GG. The effect of antihypertensive drugs and drug combinations on the incidence of new-onset type-2 diabetes mellitus. Pharmacoepidemiol Drug Saf 2007;16:979-87. (Pubitemid 47422846)
20. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000;342:905-12. (Pubitemid 30177050)
21. Lam SK, Owen A. Incident diabetes in clinical trials of antihypertensive drugs. Lancet 2007;369:1513-4; author reply 4-5.
22. Azfar RS, Seminara NM, Shin DB, Troxel AB, Margolis DJ, Gelfand JM. Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. Arch Dermatol 2012;148:995-1000.
23. Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br J Dermatol 2008;159:1331-7.
24. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008;159:895-902.
25. Li W, Han J, Hu FB, Curhan GC, Qureshi AA. Psoriasis and risk of type 2 diabetes among women and men in the United States: a population-based cohort study. J Invest Dermatol 2012;132:291-8.
26. Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 2009;145:379-82.
27. Gisondi P, Cazzaniga S, Chimenti S, Giannetti A, Maccarone M, Picardo M, et al. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare registry. J Eur Acad Dermatol Venereol 2013;27:e30-41.
28. Solomon DH, Love TJ, Canning C, Schneeweiss S. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis 2010;69:2114-7.
29. Taiwan National Health Insurance Research Database. Data Subsets: The Longitudinal Health Insurance Database. Available from: URL:http://w3.nhri.org. tw/nhird/en/Data-Subsets.html#S3. Accessed December 31, 2012.
30. Lee MS, Lin RY, Chang YT, Lai MS. The risk of developing non-melanoma skin cancer, lymphoma and melanoma in patients with psoriasis in Taiwan: a 10-year, population-based cohort study. Int J Dermatol 2012;51:1454-60.
31. WHO Collaborating Center for Drug Statistics Methodology. Defined daily dose: definition and general considerations. Available from: URL:http://www.whocc.no/ddd/definition-and-general-considera/. Accessed December 31, 2012.
32. Stricker BH, Stijnen T. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. Eur J Epidemiol 2010;25:245-51.
33. Hanley AJG, Festa A, D'Agostino RB, Wagenknecht LE, Savage PJ, Tracy RP, et al. Metabolic and inflammation variable clusters and prediction of type 2 diabetes. Diabetes 2004;53:1773-81.
34. Natali A, Toschi E, Baldeweg S, Ciociaro D, Favilla S, Saccà L, et al. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes 2006;55:1133-40. (Pubitemid 44100192)
35. Matheson DS, Green B, Hoar DI. The influence of methotrexate and thymidine on the human natural killer cell function in vitro. J Immunol 1983;131:1619-21. (Pubitemid 13010124)
36. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7. (Pubitemid 34304256)
37. Su YS, Yu HS, Li WC, Ko YC, Chen GS, Wu CS, et al. Psoriasis as initiator or amplifier of the systemic inflammatory march: impact on development of severe vascular events and implications for treatment strategy. J Eur Acad Dermatol Venereol 2013;27:876-83.
38. Tsai T-F, Wang T-S, Hung S-T, Tsai PIC, Schenkel B, Zhang M, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011;63:40-6.
39. Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol 2008;20:416-22.
40. Wolf N, Quaranta M, Prescott NJ, Allen M, Smith R, Burden AD, et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet 2008;45:114-6. (Pubitemid 351252875)